Chiffres calculés à partir des déclarations réglementaires officielles — .
Analystesobjectif 4.03 USD (-75%)
Détentioninitiés 0% · institutions 47.23% · vente à découvert 0.6% du flottant
En USD · au Oct 5, 2026
Interroger la machine
Recherchez et comparez les opérations d’initiés, les sociétés et leurs statistiques en langage courant. Votre question devient une requête sur les données disponibles, pas une conversation ni un conseil en investissement.
Données de Burning Rock Biotech Ltd uniquement. Pas de recherche web. Les statistiques globales d’un initié sont exclues.
Une recherche exécutée consomme un crédit, même sans résultat. Les erreurs et les questions non prises en charge ne consomment rien.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Source des informations de marché · Oct 5, 2026
Identité selon la SEC · Oct 5, 2026
Chronologie sur le marché · historique complet
8 achats— cours de clôturebarre = volume usd, échelle √cliquez sur une période pour filtrer le tableau
| Initié | Type | Valeur · USD | Signaux | Détail |
|---|---|---|---|---|
| Han Yushenghistorique | Achat | $216.4K | conv 45 |
| Han Yushenghistorique | Achat | $44.9K | conv 32 | SEC |
| Han Yushenghistorique | Achat | $779.7K | conv 33 | SEC |
| Han Yushenghistorique | Achat | $2M | conv 34 | SEC |
| Han Yushenghistorique | Achat | $1M | conv 33 | SEC |
| Han Yushenghistorique | Achat | $1.9M | conv 43 | SEC |
| Han Yushenghistorique | Achat | $199.1K | conv 32 | SEC |
| Han Yushenghistorique | Achat | $5.5M | conv 51Premier en 12 mois | SEC |